Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium.
Adenosine and adenosine A(2A) receptor agonists have been shown to limit myocardial infarct size when given at vasodilatory doses during reperfusion. This beneficial effect is thought to be due, in part, to stimulation of adenosine A(2A) receptors on inflammatory cells. The specific aims of this study were to determine whether the anti-inflammatory and cardioprotective properties of a novel adenosine A(2A) receptor agonist, ATL-146e (ATL), alone or in combination with the phosphodiesterase IV inhibitor rolipram would occur using very low, nonvasodilating doses. In a canine model of reperfused myocardial infarction, low-dose ATL given alone reduced infarct size by 45% (P < 0.05 vs. control). When ATL was combined with a very low dose of rolipram (0.001 microg.kg(-1).min(-1)), a marked reduction in P-selectin expression and neutrophil infiltration (51% lower; P < 0.001 vs. control) was seen and the infarct size reduction (58% lower; P < 0.01 vs. control) was greater than observed with ATL (45% lower; P < 0.05) or rolipram (33% lower; P < 0.05) alone. In conclusion, a low, nonvasodilating dose of ATL, a highly selective adenosine A(2A) receptor agonist, reduced infarct size after reperfusion. Furthermore, combining ATL and the phosphodiesterase IV inhibitor rolipram reduced infarct size even more than either agent alone. Such combination therapy may be beneficial clinically by potentiating cardioprotection after coronary reperfusion at doses far below those producing vasodilatation or side effects.
Glover
David K
DK
Department of Internal Medicine, Division of Cardiology, University of Virginia, PO Box 800500, UVA Health System, Cobb Hall, Rm. 1010, Hospital Drive, Charlottesville, VA 22908-0500, USA. dglover@virginia.edu
Riou
Laurent M
LM
Ruiz
Mirta
M
Sullivan
Gail W
GW
Linden
Joel
J
Rieger
Jayson M
JM
Macdonald
Timothy L
TL
Watson
Denny D
DD
Beller
George A
GA
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D058908:Adenosine A2 Receptor Agonists; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology; D003326:Coronary Circulation / Q000187:drug effects; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology*; D004285:Dogs; D004359:Drug Therapy, Combination; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009205:Myocarditis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011687:Purines / Q000494:pharmacology*; D016897:Respiratory Burst / Q000187:drug effects; D020889:Rolipram / Q000494:pharmacology
C431129:ATL 146e; D058908:Adenosine A2 Receptor Agonists; D002316:Cardiotonic Agents; D003509:Cyclohexanecarboxylic Acids; D010726:Phosphodiesterase Inhibitors; D011687:Purines; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram